Inhibition of phenprocoumon anticoagulation by carbamazepine

European Neuropsychopharmacology

Volumn 10, Issue 3, 2000, Pages 219-221

  Schlienger, Raymond ^a,b   Kurmann, Markus ^a   Drewe, Jürgen ^a,b   Müller Spahn, Franz ^c   Seifritz, Erich ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Anticoagulants; Carbamazepine; Cytochrome P450; Drug interactions; Phenprocoumon; Prothrombin time

Indexed keywords

ANTICOAGULANT AGENT; CARBAMAZEPINE; CYTOCHROME P450; DICOUMAROL; PHENPROCOUMON; VALPROIC ACID; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; DEEP VEIN THROMBOSIS; DRUG CHOICE; DRUG INHIBITION; DRUG WITHDRAWAL; DYSTHYMIA; ENZYME INDUCTION; FEMALE; HUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME;

EID: 0033997306     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(00)00056-0     Document Type: Article

References (16)

1. Anderson G.D. A mechanistic approach to antiepileptic drug interactions. Ann. Pharmacother. 32:1998;554-563.
2. Böttcher T., Buchmann J., Zettl U.K., Benecke R. Carbamazepine-phenprocoumon interaction. Eur. Neurol. 38:1997;132-133.
3. Bourgeois B.F. New antiepileptic drugs. Arch. Neurol. 55:1998;1181-1183.
4. Denbow C.E., Fraser H.S. Clinically significant hemorrhage due to warfarin-carbamazepine interaction. South. Med. J. 83:1990;981.
5. Dollery C. Therapeutic Drugs. 1999;Churchill Livingstone, Edinburgh.
6. Goodwin F.K. Anticonvulsant therapy and suicide risk in affective disorders. J. Clin. Psychiatry. 60:(Suppl. 2):1999;89-93.
7. Hansen J.M., Siersbaek-Nielsen K., Kristensen M., Skovsted L., Christensen L.K. Effect of diphenylhydantoin on the metabolism of dicoumarol in man. Acta Med. Scand. 189:1971;15-19.
8. Hansen J.M., Siersboek-Nielsen K., Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin. Pharmacol. Ther. 12:1971;539-543.
9. Kendall A.G., Boivin M. Warfarin-carbamazepine interaction [letter]. Ann. Intern. Med. 94:1981;280.
10. Massey E.W. Effect of carbamazepine on coumadin metabolism [letter]. Ann. Neurol. 13:1983;691-692.
11. Physicians' Desk Reference. 1999;Medical Economics, Montvale, NJ.
12. Post R.M. Comparative pharmacology of bipolar disorder and schizophrenia. Schizophr. Res. 39:1999;153-158.
13. Ross J.R., Beeley L. Interaction between carbamazepine and warfarin. Br. Med. J. 280:1980;1415-1416.
14. Spahn H., Kirch W., Mutschler E., Ohnhaus E.E., Kitteringham N.R., Logering H.J., Paar D. Pharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol. Br. J. Clin. Pharmacol. 17:(Suppl. 1):1984;97S-102S.
15. Spina E., Pisani F., Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin. Pharmacokinet. 31:1996;198-214.
16. Stockley I.H. Drug Interactions: A Source Book for Adverse Drug Interactions, their Mechanisms, Clinical Importance and Management. 1996;Pharmaceutical Press, London.